Clinical Efficacy, Extrapyramidal Symptoms and Serum Levels

Influence of Administration Schedules and Concomitant Drugs on Serum Bromperidol Concentrations

Yasuo Fujii, Masato Tateyama, Mamoru Kamisada, Akira Tanoue, Maki Takamiya, Shinichiro Nakajima, Hitoshi Itoh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Abstract: Bromperidol (4 or 12 mg per day) was administered to 18 newly admitted schizophrenics and 29 chronic schizophrenic inpatients once or four times a day and the two dose schedules were compared. The bromperidol levels in the four‐times‐a‐day group were significantly higher than those in the once‐a‐day group and the daily variation in the serum level of the agent was markedly wider in the latter than in the former patients. The incidence and severity of extrapyramidal symptoms were not significantly different between the two. A clear relationship was not present between the serum levels and the development of extrapyramidal symptoms. The bromperidol serum values were not correlated with the therapeutic response but, at more than 5 ng per ml, there might be a positive correlation between the bromperidol levels and clinical efficacy in the newly admitted schizophrenics. As for concomitant medication, levomepromazine may raise the bromperidol serum level. An anti‐parkinson drug failed to depress the bromperidol level.

Original languageEnglish
Pages (from-to)121-136
Number of pages16
JournalPsychiatry and Clinical Neurosciences
Volume38
Issue number2
DOIs
Publication statusPublished - 1984 Jan 1

Fingerprint

Drug Administration Schedule
Serum
Methotrimeprazine
Antiparkinson Agents
bromperidol
Inpatients
Appointments and Schedules
Incidence

Keywords

  • administration schedule
  • bromperidol
  • efficacy
  • extrapyramidal symptoms
  • schizophrenia
  • serum levels

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Clinical Efficacy, Extrapyramidal Symptoms and Serum Levels : Influence of Administration Schedules and Concomitant Drugs on Serum Bromperidol Concentrations. / Fujii, Yasuo; Tateyama, Masato; Kamisada, Mamoru; Tanoue, Akira; Takamiya, Maki; Nakajima, Shinichiro; Itoh, Hitoshi.

In: Psychiatry and Clinical Neurosciences, Vol. 38, No. 2, 01.01.1984, p. 121-136.

Research output: Contribution to journalArticle

Fujii, Yasuo ; Tateyama, Masato ; Kamisada, Mamoru ; Tanoue, Akira ; Takamiya, Maki ; Nakajima, Shinichiro ; Itoh, Hitoshi. / Clinical Efficacy, Extrapyramidal Symptoms and Serum Levels : Influence of Administration Schedules and Concomitant Drugs on Serum Bromperidol Concentrations. In: Psychiatry and Clinical Neurosciences. 1984 ; Vol. 38, No. 2. pp. 121-136.
@article{8837ac4e02e749228bfae48ccf80af69,
title = "Clinical Efficacy, Extrapyramidal Symptoms and Serum Levels: Influence of Administration Schedules and Concomitant Drugs on Serum Bromperidol Concentrations",
abstract = "Abstract: Bromperidol (4 or 12 mg per day) was administered to 18 newly admitted schizophrenics and 29 chronic schizophrenic inpatients once or four times a day and the two dose schedules were compared. The bromperidol levels in the four‐times‐a‐day group were significantly higher than those in the once‐a‐day group and the daily variation in the serum level of the agent was markedly wider in the latter than in the former patients. The incidence and severity of extrapyramidal symptoms were not significantly different between the two. A clear relationship was not present between the serum levels and the development of extrapyramidal symptoms. The bromperidol serum values were not correlated with the therapeutic response but, at more than 5 ng per ml, there might be a positive correlation between the bromperidol levels and clinical efficacy in the newly admitted schizophrenics. As for concomitant medication, levomepromazine may raise the bromperidol serum level. An anti‐parkinson drug failed to depress the bromperidol level.",
keywords = "administration schedule, bromperidol, efficacy, extrapyramidal symptoms, schizophrenia, serum levels",
author = "Yasuo Fujii and Masato Tateyama and Mamoru Kamisada and Akira Tanoue and Maki Takamiya and Shinichiro Nakajima and Hitoshi Itoh",
year = "1984",
month = "1",
day = "1",
doi = "10.1111/j.1440-1819.1984.tb00360.x",
language = "English",
volume = "38",
pages = "121--136",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Clinical Efficacy, Extrapyramidal Symptoms and Serum Levels

T2 - Influence of Administration Schedules and Concomitant Drugs on Serum Bromperidol Concentrations

AU - Fujii, Yasuo

AU - Tateyama, Masato

AU - Kamisada, Mamoru

AU - Tanoue, Akira

AU - Takamiya, Maki

AU - Nakajima, Shinichiro

AU - Itoh, Hitoshi

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Abstract: Bromperidol (4 or 12 mg per day) was administered to 18 newly admitted schizophrenics and 29 chronic schizophrenic inpatients once or four times a day and the two dose schedules were compared. The bromperidol levels in the four‐times‐a‐day group were significantly higher than those in the once‐a‐day group and the daily variation in the serum level of the agent was markedly wider in the latter than in the former patients. The incidence and severity of extrapyramidal symptoms were not significantly different between the two. A clear relationship was not present between the serum levels and the development of extrapyramidal symptoms. The bromperidol serum values were not correlated with the therapeutic response but, at more than 5 ng per ml, there might be a positive correlation between the bromperidol levels and clinical efficacy in the newly admitted schizophrenics. As for concomitant medication, levomepromazine may raise the bromperidol serum level. An anti‐parkinson drug failed to depress the bromperidol level.

AB - Abstract: Bromperidol (4 or 12 mg per day) was administered to 18 newly admitted schizophrenics and 29 chronic schizophrenic inpatients once or four times a day and the two dose schedules were compared. The bromperidol levels in the four‐times‐a‐day group were significantly higher than those in the once‐a‐day group and the daily variation in the serum level of the agent was markedly wider in the latter than in the former patients. The incidence and severity of extrapyramidal symptoms were not significantly different between the two. A clear relationship was not present between the serum levels and the development of extrapyramidal symptoms. The bromperidol serum values were not correlated with the therapeutic response but, at more than 5 ng per ml, there might be a positive correlation between the bromperidol levels and clinical efficacy in the newly admitted schizophrenics. As for concomitant medication, levomepromazine may raise the bromperidol serum level. An anti‐parkinson drug failed to depress the bromperidol level.

KW - administration schedule

KW - bromperidol

KW - efficacy

KW - extrapyramidal symptoms

KW - schizophrenia

KW - serum levels

UR - http://www.scopus.com/inward/record.url?scp=0021633973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021633973&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1819.1984.tb00360.x

DO - 10.1111/j.1440-1819.1984.tb00360.x

M3 - Article

VL - 38

SP - 121

EP - 136

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 2

ER -